Discouraging economic data from around the globe have heightened fears that another recession is on the way. That sent the Dow Jones industrial average fell 419 points -- a return to the wild swings that gripped the stock market last week.
Fresh evidence emerged Thursday that U.S. home sales and manufacturing are weakening. Signs also surfaced that European banks are increasingly burdened by the region's debt crisis and sputtering economy.
Stocks were only part of a dramatic day across the financial markets. The price of oil fell more than $5, gold set another record, the government's 10-year Treasury note hit its lowest yield, and the average mortgage rate fell to its lowest in at least 40 years.
The selling began in Asia, where Japanese exports fell for a fifth straight month, and continued in Europe, where bank stocks were hammered because of worries about debt problems there, which have proved hard to contain.
On Wall Street, the losses wiped out much of the roughly 700 points that the Dow had gained over five days. Some investors who bought in the middle of last week decided to sell after they were confronted with a raft of bad news about the economy.
Here is a look at some of the movers in healthcare, led by Kensey Nash Corporation (NASDAQ:KNSY) whose shares rose over 4% when they raised fiscal 2012 guidance and expects revenue to be approximately $92 million, representing an approximate 28% increase from fiscal 201. a medical device company primarily focused in the field of regenerative medicine, which is the application of devices, materials and other therapies to help repair damaged or diseased tissues :
Gainers (% price change)
Kensey Nash Corporation
Array BioPharma Inc.
RTI Biologics Inc.
LeMaitre Vascular, Inc.
Losers (% price change)
Gentium S.p.A. (ADR)
Amarin Corp. plc (ADR)
Summer Infant, Inc.
Hansen Medical, Inc.
Most Actives (dollar volume)
Johnson & Johnson
Merck & Co., Inc.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites